[Expression of parafibromin in human osteosarcoma of the jaws].
OBJECTIVE
To investigate the expression of parafibromin in osteosarcoma of the jaws (JOS) and to explore its effects on tumorigenesis and progression.


METHODS
The expression of parafibromin was studied in 47 JOS and 11 ossifying fibroma of the jaws (JOF) by immunohistochemically staining.


RESULTS
In JOS, the high, medium and low levels of parafibromin expression were detected in 48.9% (23/47), 40.4% (19/47) ,and 10.7% (5/47) of the cases, respectively; correspondingly, the different expressions were seen in 90.9% (10/11), 9.1% (1/11), and 0.0% (0) JOF cases respectively. The difference between JOS and JOF groups was significantly different (U=147.5,P=0.012). In highly differentiated JOS, the expression of parafibromin was significantly higher than that in the conventional JOS (U=71.0,P=0.021) but there were no statistically correlations between the expression of parafibromin and clinical-pathological parameters of JOS (P>0.05).


CONCLUSIONS
It is possible that the down-regulation of parafibromin may be associated with the differentiation and malignant degree of JOS.
Department of Pathology, Peking University School and Hospital of Stomatology, Beijing,China.
Zi-han
ZH
Sima
Yan
Y
Chen
Tie-jun
TJ
Li
D000328:Adult; D000368:Aged; D015536:Down-Regulation; D005260:Female; D018214:Fibroma, Ossifying / Q000378:metabolism*; D006801:Humans; D007573:Jaw Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
C454900:CDC73 protein, human; D025521:Tumor Suppressor Proteins